AIMS: This study examines the utility of individual drug use and treatment characteristics for predicting in-treatment performance and post-treatment outcomes over a 1-year period. DESIGN, SETTING AND PARTICIPANTS: Data were collected from 420 adults who participated in the Methamphetamine Treatment Project (MTP), a multi-site study of randomly assigned treatment formethamphetamine dependence. Interviews were conducted at baseline, during treatment and during three follow-up time-points: treatment discharge and at 6 and 12 months following admission. MEASUREMENTS: The Addiction Severity Index (ASI); the Craving, Frequency, Intensity and Duration Estimate (CFIDE); and laboratory urinalysis results were used in the current study. FINDINGS: Analyses addressed both in-treatment performance and post-treatment outcomes. The most consistent finding is that pre-treatment methamphetamine use predicts in-treatment performance and post-treatment outcomes. No one variable predicted all in-treatment performance measures; however, gender, route of administration and pre-treatment methamphetamine use were significant predictors. Similarly, post-treatment outcomes were predicted by a range of variables, although pre-treatment methamphetamine use was significantly associated with each post-treatment outcome. CONCLUSIONS: These findings provide useful empirical information about treatment outcomes for methamphetamine abusers, and highlight the utility of assessing individual and in-treatment characteristics in the development of appropriate treatment plans.
RCT Entities:
AIMS: This study examines the utility of individual drug use and treatment characteristics for predicting in-treatment performance and post-treatment outcomes over a 1-year period. DESIGN, SETTING AND PARTICIPANTS: Data were collected from 420 adults who participated in the Methamphetamine Treatment Project (MTP), a multi-site study of randomly assigned treatment for methamphetamine dependence. Interviews were conducted at baseline, during treatment and during three follow-up time-points: treatment discharge and at 6 and 12 months following admission. MEASUREMENTS: The Addiction Severity Index (ASI); the Craving, Frequency, Intensity and Duration Estimate (CFIDE); and laboratory urinalysis results were used in the current study. FINDINGS: Analyses addressed both in-treatment performance and post-treatment outcomes. The most consistent finding is that pre-treatment methamphetamine use predicts in-treatment performance and post-treatment outcomes. No one variable predicted all in-treatment performance measures; however, gender, route of administration and pre-treatment methamphetamine use were significant predictors. Similarly, post-treatment outcomes were predicted by a range of variables, although pre-treatment methamphetamine use was significantly associated with each post-treatment outcome. CONCLUSIONS: These findings provide useful empirical information about treatment outcomes for methamphetamine abusers, and highlight the utility of assessing individual and in-treatment characteristics in the development of appropriate treatment plans.
Authors: Frank N Angelo; Michael G McDonell; Michael R Lewin; Debra Srebnik; Jessica Lowe; John Roll; Richard Ries Journal: Drug Alcohol Depend Date: 2012-12-27 Impact factor: 4.492
Authors: Michael D Hambuchen; Daniela Rüedi-Bettschen; D Keith Williams; Howard Hendrickson; S Michael Owens Journal: Vaccine Date: 2014-09-22 Impact factor: 3.641
Authors: Andy C Dean; Edythe D London; Catherine A Sugar; Christina M R Kitchen; Aimee-Noelle Swanson; Keith G Heinzerling; Ari D Kalechstein; Steven Shoptaw Journal: Drug Alcohol Depend Date: 2009-07-15 Impact factor: 4.492